32 completed, 9 recruiting, 8 active not recruiting, 3 not yet recruiting. 27 Phase 3, 21 Phase 1, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 10, Active not recruiting 8, Recruiting 8, Not yet recruiting 1 |
| Phase 1 | 21 | Completed 20, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 4 | 2 | Not yet recruiting 2 |
Follow orforglipron: new trials by email Literature Review of orforglipron trials Research Report on orforglipron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 192 | 2026-12-01 | 2026-10-13 |
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation Phentermine Pill, Orforglipron - Obesity | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 60 | 2026-11-01 | 2026-07-27 |
| PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses Orforglipron - Diabete Type 2, Pharmacogenomic Drug Interaction | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2026-10-01 | 2026-08-31 |
| IBI3042 Study in Healthy Participants and Overweight or Obese Participants Orforglipron, Matching Placebo, IBI3042 - Overweight, Healthy Participants | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 104 | 2026-09-07 | 2026-09-11 |
| A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity Orforglipron, Placebo - Overweight, Prediabetic State | Phase 3 | Recruiting | Eli Lilly and Company | 2001 | 2026-08-26 | 2026-11-05 |
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus | Phase 3 | Recruiting | Eli Lilly and Company | 130 | 2026-07-15 | 2026-10-08 |
| A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes Orforglipron, Dulaglutide - Diabetes Mellitus, Type 2 | Phase 3 | Recruiting | Eli Lilly and Company | 170 | 2026-07-08 | 2026-11-05 |
| A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Orforglipron, Placebo - Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | Phase 3 | Recruiting | Eli Lilly and Company | 7140 | 2025-12-01 | 2026-11-04 |
| Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Orforglipron, Placebo - Peripheral Arterial Disease | Phase 3 | Recruiting | Eli Lilly and Company | 1205 | 2025-10-31 | 2026-11-04 |
| A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight Orforglipron, Placebo - Urinary Incontinence,Stress | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2025-09-30 | 2026-11-04 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee Orforglipron, Placebo - Osteoarthritis | Phase 3 | Active not recruiting | Eli Lilly and Company | 800 | 2025-09-15 | 2026-10-08 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Active not recruiting | Eli Lilly and Company | 600 | 2025-05-19 | 2026-04-20 |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Active not recruiting | Eli Lilly and Company | 1400 | 2025-05-15 | 2026-07-31 |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity Orforglipron, Placebo - Obesity, Overweight | Phase 3 | Active not recruiting | Eli Lilly and Company | 800 | 2025-05-15 | 2026-07-29 |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Orforglipron, Placebo - Hypertension, Overweight or Obesity | Phase 3 | Active not recruiting | Eli Lilly and Company | 487 | 2025-04-30 | 2026-05-29 |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) Orforglipron, Placebo - Hypertension | Phase 3 | Active not recruiting | Eli Lilly and Company | 974 | 2025-04-30 | 2026-05-29 |
| A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 Orforglipron, Placebo - Hypertension | Phase 3 | Active not recruiting | Eli Lilly and Company | 487 | 2025-04-30 | 2026-05-29 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight Orforglipron, Placebo - Obesity, Overweight | Phase 1 | Completed | Eli Lilly and Company | 120 | 2025-02-17 | 2026-02-25 |
| A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants Orforglipron - Healthy | Phase 1 | Completed | Eli Lilly and Company | 86 | 2024-12-13 | 2025-06-24 |
| A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants Orforglipron, Midazolam, Quinidine - Healthy | Phase 1 | Completed | Eli Lilly and Company | 27 | 2024-12-06 | 2026-05-26 |
Showing 20 of 52. Sign in to see all of them.
Obesity (23) · Overweight (20) · Diabetes Mellitus, Type 2 (15) · Hypertension (3) · Nutrition Disorders (2) · Renal Insufficiency, Chronic (2) · Arthritis (1) · Behavior (1) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Endocrine System Diseases (1) · Fasting (1) · Feeding Behavior (1) · Glucose Metabolism Disorders (1) · Heart Diseases (1)
Eli Lilly and Company (49) · Massachusetts General Hospital (2) · Innovent Biologics (Suzhou) Co. Ltd. (1)
United States (37) · Japan (23) · China (22) · Puerto Rico (17) · Germany (14) · Argentina (13) · Czechia (12) · India (12) · Mexico (11) · Poland (10) · Spain (10) · Brazil (9) · South Korea (9) · Greece (7) · Taiwan (7)
PMID 38402332, PMID 40481478, PMID 42577069, PMID 37351564, PMID 37369232, PMID 40544435, PMID 40960239, PMID 41275875, PMID 41765029, PMID 41994902, PMID 42120723, PMID 42251769, PMID 42259339, PMID 42383207, PMID 42607698, PMID 42750540, PMID 42815506, PMID 42830762
2025 (8), 2023 (2), R01DK148455 (1)